NYSE:TEVA

Stock Analysis Report

Executive Summary

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.

Snowflake

Fundamentals

Fair value with moderate growth potential.

Risks

  • Teva Pharmaceutical Industries has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-14.5%

NYSE:TEVA

-0.9%

US Pharmaceuticals

-1.2%

US Market


1 Year Return

-65.5%

NYSE:TEVA

3.7%

US Pharmaceuticals

3.4%

US Market

TEVA underperformed the Pharmaceuticals industry which returned 4.7% over the past year.

TEVA underperformed the Market in United States of America which returned 3.9% over the past year.


Share holder returns

TEVAIndustryMarket
7 Day-14.5%-0.9%-1.2%
30 Day-3.3%-4.0%1.2%
90 Day-44.9%0.8%1.7%
1 Year-65.5%-65.5%6.2%3.7%5.7%3.4%
3 Year-84.9%-85.5%7.8%0.2%45.0%35.5%
5 Year-84.2%-85.5%25.6%12.1%59.3%41.6%

Price Volatility Vs. Market

How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Teva Pharmaceutical Industries undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Teva Pharmaceutical Industries's share price is below the future cash flow value, and at a moderate discount (> 20%).

Teva Pharmaceutical Industries's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Teva Pharmaceutical Industries is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Teva Pharmaceutical Industries is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Teva Pharmaceutical Industries, we can't assess if its growth is good value.


Price Based on Value of Assets

Teva Pharmaceutical Industries is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Teva Pharmaceutical Industries expected to perform in the next 1 to 3 years based on estimates from 23 analysts?

64.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Teva Pharmaceutical Industries's revenue is expected to grow by 0.7% yearly, however this is not considered high growth (20% yearly).

Teva Pharmaceutical Industries's earnings are expected to grow significantly at over 20% yearly.

Teva Pharmaceutical Industries's revenue growth is positive but not above the United States of America market average.

Teva Pharmaceutical Industries's earnings growth is expected to exceed the United States of America market average.

Teva Pharmaceutical Industries's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Teva Pharmaceutical Industries is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Teva Pharmaceutical Industries performed over the past 5 years?

-64.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Teva Pharmaceutical Industries does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Teva Pharmaceutical Industries's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Teva Pharmaceutical Industries's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Teva Pharmaceutical Industries has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Teva Pharmaceutical Industries has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Teva Pharmaceutical Industries improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Teva Pharmaceutical Industries's financial position?


Financial Position Analysis

Teva Pharmaceutical Industries's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Teva Pharmaceutical Industries's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Teva Pharmaceutical Industries's level of debt (180.9%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (51.2% vs 180.9% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.5x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Teva Pharmaceutical Industries has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Teva Pharmaceutical Industries has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 41.6% per year.


Next Steps

Dividend

What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Teva Pharmaceutical Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Teva Pharmaceutical Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Teva Pharmaceutical Industries has not reported any payouts.

Unable to verify if Teva Pharmaceutical Industries's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Teva Pharmaceutical Industries has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Teva Pharmaceutical Industries's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Teva Pharmaceutical Industries's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Kåre Schultz (58yo)

1.7yrs

Tenure

US$32,469,875

Compensation

Mr. Kåre Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry  ...


CEO Compensation Analysis

Kåre's remuneration is higher than average for companies of similar size in United States of America.

Kåre's compensation has increased whilst company is loss making.


Management Age and Tenure

3.4yrs

Average Tenure

53yo

Average Age

The tenure for the Teva Pharmaceutical Industries management team is about average.


Board Age and Tenure

2.2yrs

Average Tenure

63yo

Average Age

The average tenure for the Teva Pharmaceutical Industries board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Mike McClellan (48yo)

    Executive VP & CFO

    • Tenure: 2.0yrs
    • Compensation: $4.95m
  • Kevin Mannix

    Senior Vice President of Investor Relations

  • Hafrun Fridriksdottir (57yo)

    Executive Vice President of Global R&D

    • Tenure: 2.4yrs
    • Compensation: $5.98m
  • Kåre Schultz (58yo)

    President

    • Tenure: 1.7yrs
    • Compensation: $32.47m
  • Deborah Griffin

    Senior VP & Chief Accounting Officer

  • David Stark (50yo)

    Executive VP & Chief Legal Officer

    • Tenure: 2.7yrs
  • Mark Sabag (48yo)

    Executive Vice President of Global Human Resources

    • Tenure: 5.9yrs
    • Compensation: $5.25m
  • Lori Queisser

    Senior VP & Global Compliance Officer

    • Tenure: 4.1yrs
  • Iris Beck-Codner (53yo)

    Executive Vice President of Global Brand & Communications

    • Tenure: 5.0yrs
  • Carlo de Notaristefani (61yo)

    Executive Vice President of Global Operations

    • Tenure: 6.9yrs
    • Compensation: $7.24m

Board Members

  • Roberto Mignone (47yo)

    Independent Director

    • Tenure: 2.0yrs
    • Compensation: $241.43k
  • Kåre Schultz (58yo)

    President

    • Tenure: 1.7yrs
    • Compensation: $32.47m
  • Murray Goldberg (74yo)

    Independent Director

    • Tenure: 2.0yrs
    • Compensation: $245.71k
  • Perry Nisen (63yo)

    Independent Director

    • Tenure: 2.0yrs
    • Compensation: $211.71k
  • Chemi Peres (60yo)

    Independent Director

    • Tenure: 2.0yrs
    • Compensation: $235.53k
  • Jerry Lieberman (72yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: $250.72k
  • Amir Elstein (63yo)

    Independent Director

    • Tenure: 10.5yrs
    • Compensation: $246.32k
  • Jean-Michel Halfon (67yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: $232.68k
  • Rose Crane (59yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: $235.00k
  • Sol Barer (72yo)

    Chairman of the Board

    • Tenure: 2.4yrs
    • Compensation: $378.00k

Company Information

Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Teva Pharmaceutical Industries Limited
  • Ticker: TEVA
  • Exchange: NYSE
  • Founded: 1901
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$8.641b
  • Shares outstanding: 1.09b
  • Website: Click here

Number of Employees


Location

  • Teva Pharmaceutical Industries Limited
  • 5 Basel Street
  • Petach Tikva
  • 4951033
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TEVANYSE (New York Stock Exchange)YesADR-EACH CNV INTO 1 ORD ILS0.10USUSDFeb 1982
TEVDB (Deutsche Boerse AG)YesADR-EACH CNV INTO 1 ORD ILS0.10DEEURFeb 1982
TEVA NBMV (Bolsa Mexicana de Valores)YesADR-EACH CNV INTO 1 ORD ILS0.10MXMXNFeb 1982
TEVASWX (SIX Swiss Exchange)YesADR-EACH CNV INTO 1 ORD ILS0.10CHCHFFeb 1982
0LERLSE (London Stock Exchange)YesADR-EACH CNV INTO 1 ORD ILS0.10GBUSDFeb 1982
TEVAWBAG (Wiener Boerse AG)YesADR-EACH CNV INTO 1 ORD ILS0.10ATEURFeb 1982
TEVJ.FOTCPK (Pink Sheets LLC)Ordinary SharesUSUSDJun 1994
TEVATASE (The Tel-Aviv Stock Exchange)Ordinary SharesILILSJun 1994

Biography

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through tw ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/19 23:47
End of Day Share Price2019/07/19 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.